Sign In
Buy BIIB
$195.96
+7.13 (+3.78%)
At Close: Jun 03, 2026
Will Biogen Q4 earnings bring positive surprise amid Aduhelm woes?
04:37pm, Wednesday, 02'nd Feb 2022 Seeking Alpha
Biogen (NASDAQ:BIIB) is scheduled to announce Q4 earnings results on Thursday, February 3rd, before market open.The consensus EPS Estimate is $3.38 (-26.2% Y/Y) and the consensus…
Biotech Stock Roundup: GILD Q4 Earnings, REGN, MRNA's Regulatory Updates & More
04:27pm, Wednesday, 02'nd Feb 2022 Zacks Investment Research
Earnings updates from Gilead (GILD) and regulatory updates are among a few key highlights from the biotech sector during the past week.
Drug/Biotech Stocks Earnings on Feb 3: BIIB, LLY & MRK
01:50pm, Wednesday, 02'nd Feb 2022
Let us take a look at three drug/biotech companies, namely, BIIB, LLY and MRK, which are gearing up for their earnings release.
Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab
10:03am, Tuesday, 01'st Feb 2022
Biogen Inc BIIB has exercised its option to participate in the development and commercialization of mosunetuzumab, a CD20xCD3 T-cell engaging bispecific antibody for B-cell non-Hodgkin's lymphoma (
Biogen Inc.: Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
12:41pm, Monday, 31'st Jan 2022 FinanzNachrichten
CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that Nancy Leaming and Brian Posner will retire from Biogen''s Board of Directors, effective at the tim…
Is a Beat Likely for Biogen (BIIB) This Earnings Season?
12:20pm, Monday, 31'st Jan 2022
Investor focus is likely to be on sales of new Alzheimer's drug, Aduhelm when Biogen (BIIB) reports fourth-quarter results.
Got $10,000? These 2 Growth Stocks Are Trading Near Their 5-Year Lows
07:20am, Saturday, 29'th Jan 2022
These stocks aren't safe, but they have the potential to generate some great returns in the long run.
Biogen (BIIB) to Sell Biosimilar JV Stake to Samsung Biologics
12:19pm, Friday, 28'th Jan 2022
Biogen (BIIB) is selling its equity stake in the Samsung Bioepis joint venture to partner Samsung Biologics
Biogen Announces Cash Injection, Moves Forward With Alzheimer's Trials
11:07am, Friday, 28'th Jan 2022
Biogen Inc. ( BIIB , Financial) announced on Thursday that it has entered into an agreement that will see Samsung BioLogics ( XKRX:207940 , Financial) acquire Biogen's equity stake in the Samsung Bioe
Biogen Sells Stake in Biosimilars Venture for $2.3 Billion
05:35am, Friday, 28'th Jan 2022
Biogen will be selling its stake in a biosimilars joint venture to partner Samsung Biologics for up to $2.3 billion.
Biogen to sell stake in Samsung Bioepis for more than $2 billion (NASDAQ:BIIB)
02:24am, Friday, 28'th Jan 2022 Seeking Alpha
Biogen (BIIB) announced an agreement with Samsung Biologics whereby the company will sell its stake in the Samsung Bioepis joint venture to the South Korean partner, Samsung BioLogics,
Biogen highlights details for Phase 4 Aduhelm study in Alzheimer''s disease (NASDAQ:BIIB)
01:06pm, Thursday, 27'th Jan 2022 Seeking Alpha
Biogen (BIIB) and Eisai (ESALF) announce additional details about the Phase 4 confirmatory study, ENVISION, of Aduhelm (aducanumab-avwa) 100 mg/mL injection for intravenous use in
LABU - A Compelling Biotech Trade
04:24pm, Wednesday, 26'th Jan 2022
LABU - A Compelling Biotech Trade
Is Biogen a Buy?
10:00am, Saturday, 22'nd Jan 2022
The company is still dealing with the fallout of a controversial regulatory approval.
Biogen After the Alzheimers Drug Debacle: Time to Sell the Parts?
12:00am, Saturday, 22'nd Jan 2022 Barron''s
The Centers for Medicare and Medicaid may ensure the commercial death of Biogens controversial Alzheimers drug. And that leads at least one analyst to wonder if more radical steps need to be taken.
